174 related articles for article (PubMed ID: 8691844)
1. Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma.
Alonso DF; Farías EF; Urtreger A; Ladeda V; Vidal MC; Bal De Kier Joffé E
J Surg Oncol; 1996 Aug; 62(4):288-97. PubMed ID: 8691844
[TBL] [Abstract][Full Text] [Related]
2. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
3. Fibrin formation induced by tumor procoagulants enhances urokinase activity produced by mammary carcinoma cells.
Alonso DF; De Lorenzo MS; Tejera AM; Gomez DE
Oncol Rep; 1998; 5(1):209-12. PubMed ID: 9458324
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF
Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428.
Alonso DF; Tejera AM; Farias EF; Bal de Kier Joffe E; Gomez DE
Anticancer Res; 1998; 18(6A):4499-504. PubMed ID: 9891516
[TBL] [Abstract][Full Text] [Related]
6. Five novel hormone-responsive cell lines derived from murine mammary ductal carcinomas: in vivo and in vitro effects of estrogens and progestins.
Lanari C; Lüthy I; Lamb CA; Fabris V; Pagano E; Helguero LA; Sanjuan N; Merani S; Molinolo AA
Cancer Res; 2001 Jan; 61(1):293-302. PubMed ID: 11196177
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of aggressiveness of metastatic mouse mammary carcinoma cells by the beta2-chimaerin GAP domain.
Menna PL; Skilton G; Leskow FC; Alonso DF; Gomez DE; Kazanietz MG
Cancer Res; 2003 May; 63(9):2284-91. PubMed ID: 12727851
[TBL] [Abstract][Full Text] [Related]
8. Invasiveness in vitro of two mammary adenocarcinoma tumors with different metastasizing ability.
Puricelli L; Colombo LL; Bal de Kier Joffé E; de Lustig ES
Invasion Metastasis; 1984; 4(4):238-46. PubMed ID: 6533095
[TBL] [Abstract][Full Text] [Related]
9. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a fibroblastoid mammary carcinoma cell line (LM2) originated from a mouse adenocarcinoma.
Galli S; Colombo L; Vanzuli S; Daroqui MC; del Carmen Vidal M; Jasnis MA; Sacerdote de Lustig E; Eijan AM
Int J Oncol; 2000 Dec; 17(6):1259-65. PubMed ID: 11078814
[TBL] [Abstract][Full Text] [Related]
11. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.
Alonso DF; Farías EF; Ladeda V; Davel L; Puricelli L; Bal de Kier Joffé E
Breast Cancer Res Treat; 1996; 40(3):209-23. PubMed ID: 8883963
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 6 gene-transfected mouse mammary adenocarcinoma: tumour cell growth and metastatic potential.
Di Carlo E; Modesti A; Castrilli G; Landuzzi L; Allione A; de Giovanni C; Musso T; Musiani P
J Pathol; 1997 May; 182(1):76-85. PubMed ID: 9227345
[TBL] [Abstract][Full Text] [Related]
13. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
14. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N
Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246
[TBL] [Abstract][Full Text] [Related]
15. [MA891--an established spontaneous mouse mammary adenocarcinoma cell line and its immunologic characteristics].
Zhou Y; Luo L; Liu X; Gao P; Su Y
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1997 Aug; 19(4):273-7. PubMed ID: 10453566
[TBL] [Abstract][Full Text] [Related]
16. Characterization of biological features and chemosensitivity of a new experimental lung metastasis model originating from the MXT mouse mammary adenocarcinoma.
Farinelle S; Dedecker R; Malonne H; Werry J; Darro F; Kiss R
Anticancer Res; 1999; 19(2A):1171-80. PubMed ID: 10368671
[TBL] [Abstract][Full Text] [Related]
17. In vitro differentiation and progression of mouse mammary tumor cells.
Sonnenberg A; Daams H; Calafat J; Hilgers J
Cancer Res; 1986 Nov; 46(11):5913-22. PubMed ID: 3756929
[TBL] [Abstract][Full Text] [Related]
18. Low adhesiveness coupled with high superinvasiveness in vitro predicts the in vivo metastatic potential of a mouse mammary adenocarcinoma cell line.
Glynn SA; Adams A; Gibson B; Cronin D; Harmey JH; Clynes M
Anticancer Res; 2006; 26(2A):1001-10. PubMed ID: 16619499
[TBL] [Abstract][Full Text] [Related]
19. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray.
Li Y; Tang Y; Ye L; Liu B; Liu K; Chen J; Xue Q
J Cancer Res Clin Oncol; 2003 Jan; 129(1):43-51. PubMed ID: 12618900
[TBL] [Abstract][Full Text] [Related]
20. Tumor subpopulation interactions affecting melphalan sensitivity in palpable mouse mammary tumors.
Miller BE; Machemer T; Lehotan M; Heppner GH
Cancer Res; 1991 Aug; 51(16):4378-87. PubMed ID: 1868461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
